Open AccessCirculating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer
Author(s) -
Simpa S. Salami,
Udit Singhal,
Daniel E. Spratt,
Ganesh S. Palapattu,
Brent K. Hollenbeck,
Joseph D. Schonhoft,
Ryon P. Graf,
Jessica Louw,
Adam Jendrisak,
Lyndsey Dugan,
Yipeng Wang,
Scott A. Tomlins,
Ryan Dittamore,
Felix Y. Feng,
Todd M. Morgan
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00352
Subject(s) - prostate cancer , circulating tumor cell , medicine , biochemical recurrence , pten , oncology , androgen deprivation therapy , androgen receptor , cancer , cytokeratin , prostatectomy , prostate , radiation therapy , cancer research , metastasis , immunohistochemistry , biology , apoptosis , biochemistry , pi3k/akt/mtor pathway
Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication.